Document text
Principal Investigator: Reuben S Harris
Organization: UNIVERSITY OF MINNESOTA
Fiscal Year: 2022
Award: $7,505,644
Funding agency: National Institute of Allergy and Infectious Diseases
Core A – Administration
ABSTRACT
The primary goals of Core A – Administration are to provide leadership, logistical support, and coordinated
communication for all members and collaborators of the Midwest AViDD Center in order to expedite the
successful completion of all specific aims. The PI of Core A is Reuben Harris and the Co-I is Fang Li, which
mirrors the overall leadership arrangement with Dr. Harris as corresponding Co-PI and Li as Co-PI. The specific
aims of Core A are to 1) provide strong and consistent leadership; 2) provide services to Program scientists,
collaborators, industry partners, and Scientific Advisory Board (SAB) members; and 3) coordinate center
communications including meetings, workshops, and outreach efforts. The efficient administration of this multi-
institutional team is essential for the successful development of novel small molecules with potential to become
orally available drugs to treat SARS-CoV-2 (all projects) and other viruses with pandemic concern (at least one
other virus to be targeted by each project).
Harris and Li both have experience managing multi-investigator, matrixed grants, and they meet weekly to
coordinate center management. They are supported by a full-time Executive Administrative Coordinator, who
provides day-to-day administrative support and coordinates meetings, workshops, travel and other
communication and networking activities. The Executive Leadership Team (ExLT), which consists of Project and
Core PIs, meets monthly to review the status of scientific progress and discuss administrative business including
budgets. The ExLT will also receive quarterly go/no-go recommendations on hit-to-lead (H2L) advancement from
the HTL Committee, which may trigger appropriate budget adjustments. Core A will also coordinate an annual
workshop for all center personnel, Scientific Advisory Board (SAB) members, and Industry Partners on dates
juxtaposing an anticipated pan-AViDD consortium meeting at the NIH campus. The SAB will be appointed with
consultation from NIAID AViDD network leadership and will participate in the annual workshop and other
meetings as required by NIAID. Additional meetings of PIs, Project personnel, Core personnel, outside
collaborators, and all center-associated personnel occur on a biweekly or monthly basis as specified by each
component. Web-based zoom meetings facilitate the participation of all team members regardless of geographic
location.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Agreement><Annual Reports><Antiviral Agents><Antiviral Drugs><Antivirals><Biometrics><Biometry><Biostatistics><Budgets><Businesses><COVID crisis><COVID epidemic><COVID pandemic><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 therapy><COVID-19 treatment><COVID-19 virus><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 pandemic><COVID19 public health crisis><COVID19 therapy><COVID19 treatment><COVID19 virus><Clip><CoV-2><CoV2><Collaborations><Communication><Communities><Conflict><Conflict (Psychology)><Consult><Consultations><Data Analyses><Data Analysis><Decision Making><Development><Development and Research><Discipline><Disease Outbreaks><Drugs><E-Mail><Educational Mainstreaming><Educational workshop><Electronic Mail><Elements><Email><Event><Experimental Designs><Future><Geographic Area><Geographic Locations><Geographic Region><Geographical Location><Goals><Grant><Group Homes><Human Resources><Individual><Internet><Investigators><Lead><Leadership><Legal><Logistics><Mainstreaming><Manpower><Medial><Mediating><Medication><Mentors><Midwest><Midwest U.S.><Midwest US><Midwestern United States><Mind><Mission><NIAID><NIH><National Institute of Allergy and Infectious Disease><National Institutes of Health><On-Line Systems><Online Systems><Oral><Organization Charts><Outbreaks><Outcome><Pb element><Peer Review><Pharmaceutic Preparations><Pharmaceutical Preparations><Phone><Publications><R & D><R&D><R-Series Research Projects><R01 Mechanism><R01 Program><Reagent><Recommendation><Reporting><Research Design><Research Grants><Research Personnel><Research Project Grants><Research Projects><Researchers><Resource Sharing><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-CoV-2 therapy><SARS-CoV-2 treatment><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 pandemic><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Schedule><Scientific Publication><Scientist><Services><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome related corona virus 2><Site><Specific qualifier value><Specified><Students><Study Type><Technology><Telephone><Time><Training><Training Activity><Travel><United States National Institutes of Health><Update><Viral><Virus><Voting><WWW><Work><Workshop><Wuhan coronavirus><achievement Mainstream Education><anti-viral agents><anti-viral compound><anti-viral development><anti-viral drug development><anti-viral drugs><anti-viral medication><anti-viral therapeutic><anti-viral therapeutic development><anti-viral therapy development><anti-virals><antiviral compound><antiviral development><antiviral drug development><antiviral medication><antiviral therapeutic><antiviral therapeutic development><antiviral therapy development><conference><convention><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 therapy><coronavirus disease 2019 treatment><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 virus><data interpretation><developing anti-viral agent><developing anti-viral drug><developing anti-viral therapeutic><developing anti-viral therapy><developing antiviral agent><developing antiviral drug><developing antiviral therapeutic><developing antiviral therapy><developmental><drug discovery><drug/agent><electronic communication><experience><geographic site><hCoV19><heavy metal Pb><heavy metal lead><industrial partnership><industry partner><industry partnership><material transfer agreement><meetings><member><nCoV2><new technology><novel><novel technologies><online computer><operation><organizational structure><outreach><pandemic><pandemic disease><payment><personnel><prevent><preventing><programs><recruit><research and development><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 treatment><small molecule><social><study design><summit><symposia><symposium><training module><treat COVID-19><treat COVID19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><virology><web><web based><web site><website><world wide web>